Results 31 to 40 of about 84,856 (259)
Current Opinion in Gastroenterology, 2003 Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder characterized by strictures and dilatations of the biliary tree. The median survival has been reported to be 12 years from diagnosis but patients diagnosed during the last decade have been shown to have longer survival of a median of 18 years.
Björnsson, E, Chapman, R
openaire +2 more sources
Case Reports in Gastroenterology, 2022 A 19-year-old man visited our hospital because of diarrhea and blood and liver dysfunction. Magnetic and endoscopic retrograde cholangiography revealed diffuse narrowing of the common biliary tract and intrahepatic biliary tract.
Jin Imai +8 more
doaj +1 more source
Hepatology, 2020 Altered bile acid (BA) homeostasis is an intrinsic facet of cholestatic liver diseases, but clinical usefulness of plasma BA assessment in primary sclerosing cholangitis (PSC) remains understudied.
O. Mousa +18 more
semanticscholar +1 more source
Hepatology, 2020 T cells from patients with primary sclerosing cholangitis (PSC) show a prominent interleukin (IL)‐17 response upon stimulation with bacteria or fungi, yet the reasons for this dominant T‐helper 17 (Th17) response in PSC are not clear.
Lilly K. Kunzmann +30 more
semanticscholar +1 more source
Nature Communications, 2023 The genetic basis of primary sclerosing cholangitis has only been partially uncovered. Here, the authors perform a multitrait genome-wide association study to provide insight into the genetic etiology of primary sclerosing cholangitis risk and possible ...
Younghun Han +23 more
doaj +1 more source
Hepatology, 2020 Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC.
B. Goeppert +35 more
semanticscholar +1 more source
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
Case Reports in Oncology, 2023 The advent of checkpoint inhibitor immunotherapy has rapidly changed the landscape of the management of cancers. However, its use has also been associated with the rise of immunotherapy-related adverse effects (irAEs).
Ian Liang +2 more
doaj +1 more source
Rapid Progression of Primary Sclerosing Cholangitis Complicated with Ulcerative Colitis
Case Reports in Gastrointestinal Medicine, 2015 Primary sclerosing cholangitis is a cholestatic condition with unknown etiology and long-standing, progressive course, leading to cirrhosis and requiring orthotropic liver transplant. In approximately 80%, primary sclerosing cholangitis is accompanied by
Piotr Pardak +2 more
doaj +1 more source
Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
BMJ Open Gastroenterology, 2020 Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined ...
Wanyuan Cui +4 more
doaj +1 more source
Hepatology, 2020 Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes.
M. Deneau +33 more
semanticscholar +1 more source